Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels.
The metabolic transformation of tritium-labeled prostaglandin D2 ([3H]PGD2) was investigated in the isolated Tyrode's-perfused rabbit liver. One major product was isolated and identified in the perfusate as a new prostanoid. The structure of this metabolite was further confirmed by gas chromatography-mass spectrometry and chemical methods to be 9 alpha,11 beta,15-L-trihydroxyprosta-5-cis, 13-trans-dienoic acid, namely (9 alpha,11 beta-PGF2). This new prostanoid was found to be an inhibitor of platelet aggregation and to cause constriction of canine coronary artery strips. These results suggested that on passage through the hepatic circulation exogenous PGD2 is converted to 9 alpha,11 beta-PGF2, the latter having a biological profile which differs from that of PGD2 and PGF2 alpha.
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D015237:Dinoprost; D015232:Dinoprostone; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D010974:Platelet Aggregation / Q000187:drug effects*; D015230:Prostaglandin D2; D011457:Prostaglandins D / Q000378:metabolism*; D011458:Prostaglandins E / Q000494:pharmacology; D011460:Prostaglandins F / Q000096:biosynthesis* / Q000302:isolation & purification / Q000494:pharmacology; D011817:Rabbits; D013917:Thrombin / Q000502:physiology; D014316:Tritium; D014661:Vasoconstriction / Q000187:drug effects*
D011457:Prostaglandins D; D011458:Prostaglandins E; D011460:Prostaglandins F; D014316:Tritium; D015237:Dinoprost; D013917:Thrombin; D015232:Dinoprostone; D015230:Prostaglandin D2